FORT LAUDERDALE, Florida, July 13, 2020 — ImmunSYS, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products, today announced that it hosted a virtual Analyst Day event on Tuesday, July 7th, 2020.
Eamonn Hobbs, Chairman and CEO of ImmunSYS and Charles J. Link, Jr., M.D., Chief Medical Officer and President of ImmunSYS provided a business overview and highlighted upcoming milestones. Two world-renowned, key opinion leaders, E. David Crawford, M.D. Professor of Urology at the University of San Diego, and Steven J. O’Day, M.D., Executive Director of the John Wayne Cancer Institute and Cancer Clinic provided updates on the current prostate cancer landscape and reviewed new data on the company’s platform technology, YourVaccx. Dr. O’Day provided an in-depth review of the company’s Proof of Concept (PoC) study data that was recently presented at the 2020 AACR Virtual Annual Meeting II.
A replay of the event can be accessed on the ImmunSYS website in the ‘Publications’ section at www.immunsys.com/publications.
About ImmunSYS
ImmunSYS, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapy products to improve the lives of patients with metastatic prostate cancer and other metastatic solid tumors.
ImmunSYS is committed to bringing life-changing treatments to patients with metastatic cancer. The Company’s platform technology, YourVaccx, empowers the immune system to generate a strong anticancer effect, potentially creating abscopal effects through the combination of cryosurgical cellular lysis and the intratumoral delivery of a proprietary triple-component immunotherapeutic drug that is in development. The YourVaccx therapy has the potential to offer patients with metastatic solid tumors benefits over the existing standard of care. The company’s lead development program is the treatment of metastatic prostate cancer, followed by a pipeline of development programs for other metastatic solid tumors. For more information about the company and its programs, visit www.immunsys.com. Follow and connect with us on Twitter, Facebook, YouTube and LinkedIn.
This news release contains forward-looking statements. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and other words and terms of similar meaning. The forward-looking statements contained in this news release include, but are not limited to, statements relating to future clinical results and the effectiveness of the Company’s therapies. These forward-looking statements are subject to risks, uncertainties and other factors. Accordingly, actual results may differ significantly from those projected in the forward-looking statements contained herein. Readers should not place undue reliance on these forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof, and the Company does not undertake any obligation to update any forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.
Contacts
ImmunSYS, Inc. Joseph Gerardi, +1-518-796-6110 Executive Vice President, Chief Financial Officer [email protected]
